FDA Approves Tenecteplase for Acute Ischemic Stroke

The thrombolytic treatment, branded as TNKase and approved for adults, is administered as a 5-second IV bolus, followed by a 60-minute infusion of 25 mg.:

Source: Neurology Read More

Previous PostParamagnetic Rim Lesions and Immune Profiling in Multiple Sclerosis Progression: Simon Thebault, MD, PhD
Next PostA Patient’s Perspective on Progress and Challenges in NMOSD Treatment Advances: Sumaira Ahmed

FDA Approves Tenecteplase for Acute Ischemic Stroke

Previous PostParamagnetic Rim Lesions and Immune Profiling in Multiple Sclerosis Progression: Simon Thebault, MD, PhD

Next PostA Patient’s Perspective on Progress and Challenges in NMOSD Treatment Advances: Sumaira Ahmed

Related Posts

<![CDATA[Satralizumab Meets Primary End Point in Phase 3 METEOROID Study in MOGAD]]>

<![CDATA[Up to 8 Years of Ofatumumab Treatment Demonstrates Stable Long-term Safety Profile in Relapsing Multiple Sclerosis]]>

<![CDATA[How Early Environmental Detection Could Refine Parkinson Disease Risk Models: Rodolfo Savica, MD, PhD]]>

Categories